Regional segmentation of the Large
Volume Parental Market by Coherent Market Insights consist of North
America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North
America is expected to dominate the large volume parenteral market, owing to
increasing number of hospital admissions and cost associated with such
admission (an estimated US$ 1900 in 2013 as per Kaiser Health fact). According
to American Hospital Association factsheet 2018, an estimated 35,158,934
hospital admissions were reported in 2017, large volume parenteral is integral
part of any admission procedure, as nutrition and electrolyte support is
essential in most of the cases. According to report by Lancet Commission for
Global Surgery, 2015, large number of unmet surgical needs in Asia Pacific
region are expected to provide potential opportunity for large volume
parenteral market due to use of large volume parenteral to administer therapeutics doses or
nutrition. Parenteral nutrition plays a key role in patients who are unable to
take diet normally or unconscious. In such cases nutrition is administered
through large volume parenteral. According to study published in Journal of
Critical Care in 2017, an estimate of 40,000 people are in need of such
parenteral nutrition annually in the U.S., which in turn is driving growth of
the market.
Parenteral are sterile dosage
form that are administered through route other than oral route of
administration. They are injected into one or more layer of skin and active
ingredient directly come in contact with tissue or blood vessel. Large volume
parenteral are of two types, small volume parenteral are single or multi dosage
preparation with volume 100 ml or less quantity whereas large volume parenteral
has volume more than 100 ml.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1323
Large volume parenteral comes in
bag or bottle for intravenous administration and are used for correction of
fluid/electrolyte balance, providing nutrition such as dextrose.
Increased need of palliative care
and need for more surgical procedures to drive growth of the large volume
parenteral market
Increasing demand for palliative
care worldwide is expected to drive growth of the large volume parenteral
market, owing to use of large volume parenteral to provide electrolyte balance
and nutritional fluids. According to World Health Organization (WHO), 2017, an
estimate of 40 million people need palliative care worldwide. Around 78% among
those people, live in low- and middle-income economies and only 14% of people
in need of palliative care receives it. Disease which require high palliative
care are cardiovascular diseases (38.5%), cancer (34%), chronic respiratory
diseases (10.3%), AIDS (5.7%) and diabetes (4.6%), kidney failure, chronic
liver disease. This creates potential opportunity for large volume parenteral
market players. Increasing number of surgeries are expected to propel growth
for the large volume parenteral market worldwide. For instance, according to
World Bank statistics, in 2012, around 4511 surgeries were performed per
1,00,000 population across the globe. As per Lancet Commission for Global
Surgery, 2015, an estimate of 143 million unmet surgical need per year,
surgical need in turn drives large volume parenteral market as they are
essential part of pre and post-operative care.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/large-volume-parenteral-market-1323
Key players operating in large
volume parenteral market include Baxter International Inc., Teva Pharmaceutical
Industries Limited, Kelun Pharmaceutical Inc., BAG Healthcare GmbH, Hospira,
Inc., Patheon Inc., Otsuka Pharmaceutical, Wockhardt Ltd., Southwest
Pharmaceutical Co. Ltd., and Cook Pharmica LLC.
In January 2018, Baxter
International Inc. announced a distribution agreement for the U.S. launch of
the Arisure Closed System Transfer device, which has several component to
prevent contaminants from entering the intravenous medication delivery system.
This avoids the entry of hazardous substances while administration of therapy.
Baxter International Inc. also completed the acquisition of the Claris
Injectable Limited in July 2017, which is expected to improve Baxter’s presence
in generic injectable market.
Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1323
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment